In a study with patients with laBCC previously treated with an HHI,

LIBTAYO demonstrated durable responses1

Chart, duration of response in locally advanced BCC

Median DOR was not reached for laBCC
(range: 2.1-21.4+ months)1

Median time to response was 4.2 months (range: 2.1-13.4)1

  • Plus sign (+) denotes ongoing at last assessment.1
  • BCC=basal cell carcinoma; DOR=duration of response; HHI=hedgehog inhibitor; laBCC=locally advanced BCC.

Reference: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC.